Xbiotech Inc (XBIT) Stock Price, Quote & News

Company Profile

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inf...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 386 2900

Fax: 512 386 5505

Website: www.xbiotech.com

Address:

5217 Winnebago Lane, Austin, United States

WallstreetGenie Jun. 29 at 5:32 AM

$XBIT what’s the float on this

2 · Reply

bcobersee Jun. 28 at 7:57 AM

$XBIT more than 25x average daily volume yesterday… someone bought a lot! interesting… over 2.5 mio. shares traded

1 · Reply

bcobersee Jun. 27 at 8:41 PM

$XBIT

0 · Reply

bcobersee Jun. 26 at 7:53 PM

$XBIT rising volume… just a bit patience

0 · Reply

bcobersee Jun. 26 at 1:14 PM

$XBIT new 8K-file

0 · Reply

baj10se Jun. 20 at 9:16 PM

$XBIT what a turd.

1 · Reply

MarkZH Jun. 17 at 1:44 PM

$XBIT New study in Rheumatoid Arthritis will start 07/15/2025 with 108 patients Study completion 03/15/2026 This will be 🚀🚀 https://clinicaltrials.gov/study/NCT06590090

0 · Reply

bcobersee Jun. 4 at 7:52 PM

$XBIT one news, good volume and this will fly 🚀

1 · Reply

bcobersee Jun. 4 at 7:25 PM

$XBIT wait for it!

0 · Reply

MarkZH May. 19 at 5:12 PM

$XBIT The only way is up 🚀

0 · Reply

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

Feb 2, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud

Jan 29, 2025, 10:00 AM EST - 6 months ago

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 28, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Shareholders to Inquire about Securities Investigation

Jan 27, 2025, 11:15 AM EST - 6 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud

Jan 27, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect

Jan 26, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out

Jan 24, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Investors to Learn More About the Investigation

Jan 23, 2025, 10:00 AM EST - 6 months ago

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 22, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Investors to Connect

Jan 21, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation

Jan 19, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Stockholders to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation

Jan 17, 2025, 5:19 AM EST - 6 months ago

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Jan 16, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out

Jan 15, 2025, 11:15 AM EST - 6 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud

Jan 15, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out

Jan 14, 2025, 4:37 PM EST - 6 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Jan 14, 2025, 11:15 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect

Jan 13, 2025, 9:15 PM EST - 6 months ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.

Dec 23, 2024, 9:00 AM EST - 7 months ago

XBiotech Pauses Rheumatology program

Jun 18, 2024, 1:08 PM EDT - 1 year ago

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Jun 18, 2024, 11:35 AM EDT - 1 year ago

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

May 24, 2024, 4:08 PM EDT - 1 year ago

XBiotech: Several Shots On Goal In Big Target Market Indications

Jan 4, 2024, 9:00 AM EST - 1 year ago

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Nov 14, 2023, 9:00 AM EST - 1 year ago

Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

Sep 26, 2023, 9:00 AM EDT - 1 year ago

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Aug 30, 2023, 9:00 AM EDT - 2 years ago

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

Aug 8, 2023, 11:47 AM EDT - 2 years ago

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

WallstreetGenie Jun. 29 at 5:32 AM

$XBIT what’s the float on this

2 · Reply

bcobersee Jun. 28 at 7:57 AM

$XBIT more than 25x average daily volume yesterday… someone bought a lot! interesting… over 2.5 mio. shares traded

1 · Reply

bcobersee Jun. 27 at 8:41 PM

$XBIT

0 · Reply

bcobersee Jun. 26 at 7:53 PM

$XBIT rising volume… just a bit patience

0 · Reply

bcobersee Jun. 26 at 1:14 PM

$XBIT new 8K-file

0 · Reply

baj10se Jun. 20 at 9:16 PM

$XBIT what a turd.

1 · Reply

MarkZH Jun. 17 at 1:44 PM

$XBIT New study in Rheumatoid Arthritis will start 07/15/2025 with 108 patients Study completion 03/15/2026 This will be 🚀🚀 https://clinicaltrials.gov/study/NCT06590090

0 · Reply

bcobersee Jun. 4 at 7:52 PM

$XBIT one news, good volume and this will fly 🚀

1 · Reply

bcobersee Jun. 4 at 7:25 PM

$XBIT wait for it!

0 · Reply

MarkZH May. 19 at 5:12 PM

$XBIT The only way is up 🚀

0 · Reply

MarkZH May. 16 at 7:06 PM

$XBIT NAV per share $9 - $12 Without pipeline STRONG BUY🚀

0 · Reply

MarkZH May. 16 at 6:58 PM

$XBIT Don’t forget! They own 48 acres of land in Austin - value between $100-200m or $3.30-$6.60 per share

0 · Reply

Trekingirl May. 16 at 9:59 AM

$XBIT Anybody else like these numbers? It's true. They haven't had any income in quite some time, but they aren't land rich and dirt poor. They're land rich and filthy rich.

0 · Reply

Armonica423 May. 11 at 12:37 AM

$XBIT Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

bcobersee Apr. 29 at 11:06 AM

$XBIT

0 · Reply

WAYWARD_SUN Apr. 25 at 7:49 PM

$XBIT

0 · Reply

MarkZH Apr. 23 at 9:03 PM

$XBIT Did anyone see this?

0 · Reply

EvanWan Apr. 10 at 8:04 PM

$XBIT 🚨 NASDAQ:МYNZ in the spotlight! 🚨 МainzBiomed vs. Aurinia — traders are debating which biotech is the better bet. And if $МYNZ is already showing up in headlines next to giants like AUPH — that’s a signal, not a coincidence. 📈 Simple thesis: if people talk about it, they start buying it. And when they buy — the price moves up. 💡 Remember: hype is fuel, fundamentals are the engine. МYNZ is getting both. 🛒 Load up before this ticker is in everyone’s portfolio.

0 · Reply

BiotechAnalyst1 Apr. 1 at 4:10 PM

$XBIT Phase 2 will terminated end of 2025 https://communities.springernature.com/posts/targeting-il-1-in-metastatic-colon-cancer-a-clinical-feasibility-study-showing-promising-results-in-a-phase-1-trial?channel_id=behind-the-paper

0 · Reply

BiotechAnalyst1 Apr. 1 at 6:04 AM

$XBIT https://pmc.ncbi.nlm.nih.gov/articles/PMC11739593/

0 · Reply

BiotechAnalyst1 Mar. 25 at 5:11 PM

$XBIT - The market price for building land in austin is in the range of 1000$\m2

0 · Reply

IDontBelieveYou Mar. 24 at 1:44 PM

$XBIT shorts are gambling with their accounts here...

0 · Reply

Market Cap	88.11M
Revenue (ttm)	0.00
Net Income (ttm)	-38.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	55,100
Avg Vol	102,824
Day's Range	N/A - N/A
Shares Out	30.49M
Stochastic %K	0%
Beta	0.98
Analysts	Strong Buy
Price Target	$18.00